Cocrystal is a clinical stage biotechnology company which develops novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure based drug design technology and antiviral nucleoside chemistry to create first in class and best in class antiviral drug candidates. Our focus is to pursue the development and commercialization of broad spectrum antiviral drug candidates that will transform the treatment and prophylaxis of hepatitis C, Influenza, and Norovirus. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.
Quote | Cocrystal Pharma Inc. (NASDAQ:COCP)
Last: | $1.51 |
---|---|
Change Percent: | -3.33% |
Open: | $1.59 |
Close: | $1.562 |
High: | $1.59 |
Low: | $1.5 |
Volume: | 2,903 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Cocrystal Pharma Inc. (NASDAQ:COCP)
2024-03-28 14:47:48 ET More on Cocrystal Pharma Seeking Alpha’s Quant Rating on Cocrystal Pharma Historical earnings data for Cocrystal Pharma Financial information for Cocrystal Pharma Read the full article on Seeking Alpha For further details...
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum PB2 inhibitor Topline data expected in 2024 from Phase 2a influenza A human challen...
Message Board Posts | Cocrystal Pharma Inc. (NASDAQ:COCP)
Subject | By | Source | When |
---|---|---|---|
$COCP Cocrystal Pharma Inc | mick | investorshub | 04/30/2023 11:27:55 PM |
This is a great time to add a | tredenwater2 | investorshub | 04/28/2023 10:04:06 PM |
https://en.wikipedia.org/wiki/Fred_Hassan | joe_techi | investorshub | 04/27/2023 8:19:18 PM |
$COCP Cocrystal Pharma Inc | mick | investorshub | 04/25/2023 5:31:18 PM |
hi dare friend , the scoop school still | mick | investorshub | 04/25/2023 5:30:55 PM |
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum PB2 inhibitor Topline data expected in 2024 from Phase 2a influenza A human challen...
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New D...
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replicat...